---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-012895"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T22:59:55.211948+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InfuSystem reports record 2025 revenue $143.4M, adj. EBITDA $31.5M, net leverage 0.52x

## Summary
- 2025 net revenue $143.4M, up 6.3% YoY from $134.9M; seven consecutive years of record revenue.
- 2025 adjusted EBITDA of $31.5M (21.9% margin) vs $25.3M (18.8%) in 2024; cash flow from operations $24.4M.
- Patient Services revenue $86.5M (60% of total), Device Solutions $56.9M (40%); gross margin 56.0%.
- Share repurchase program: $11.0M bought back through Dec 31, 2025; $20M authorization expires June 2026.
- Net leverage 0.52x, debt/equity 0.75x, total available liquidity $58.2M.

## SEC filing metadata
- accession: 0001628280-26-012895
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828026012895/0001628280-26-012895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828026012895/infu-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-012895
- JSON: https://secwatch.observer/filing/0001628280-26-012895.json
- Plain text: https://secwatch.observer/filing/0001628280-26-012895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.